Finepoint Capital LP Spring Works Therapeutics, Inc. Call Options Transaction History
Finepoint Capital LP
- $963 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SWTX
# of Institutions
237Shares Held
68.9MCall Options Held
144KPut Options Held
257K-
Vanguard Group Inc Valley Forge, PA6.71MShares$239 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$200 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.84MShares$137 Million4.54% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.52MShares$125 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA3.42MShares$122 Million5.82% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.22B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...